文献速递糖尿病

在EXSCEL试验中评估接受艾塞那肽治疗的2型糖尿病患者的医疗资源使用、费用与生活质量

Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
PubMed 文献 · Diabetes Care · 2019-12-05

EXSCEL试验随机分配14,752例2型糖尿病患者接受每周一次艾塞那肽(EQW)或安慰剂联合常规降糖治疗,比较医疗资源使用、费用和EQ-5D健康效用。EQW组平均住院天数较少,非研究降糖药物费用较低,但计入艾塞那肽费用后总费用显著更高;健康效用无显著差异。

要点

  • EQW组平均住院天数较安慰剂组少0.41天(7.05 vs 7.46天;相对率比0.91;P=0.05)。
  • EQW组非研究降糖药物平均费用较安慰剂组低约1,600美元(P=0.01)。
  • 计入艾塞那肽费用后,EQW组总平均费用显著高于安慰剂组。

核心结论

  • EQW组医疗费用低于安慰剂组,但计入品牌艾塞那肽费用后总费用显著更高。

研究设计与样本

  • EXSCEL试验的试验内评估,纳入14,752例2型糖尿病患者,随机分配至每周一次艾塞那肽(EQW)或安慰剂联合常规糖尿病治疗。

主要发现

  • 患者平均随访3.3年,EQW组较安慰剂组平均住院天数少0.41天(7.05 vs 7.46天;相对率比0.91;P=0.05)。
  • 门诊就诊率相似,住院和门诊总费用也相似。
  • 研究期间EQW组非研究降糖药物平均费用较安慰剂组低约1,600美元(P=0.01)。
  • 排除研究药物的试验内总费用EQW组低于安慰剂组(28,907美元 vs 30,914美元;P≤0.01)。
  • 计入EQW估算费用后,EQW组总平均费用显著高于安慰剂组(42,697美元 vs 30,914美元;P<0.01)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare medical resource use, costs, and health utilities for 14,752 patients with type 2 diabetes who were randomized to once-weekly exenatide (EQW) or placebo in addition to usual diabetes care in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). RESEARCH DESIGN AND METHODS: Medical resource use data and responses to the EuroQol 5-Dimension (EQ-5D) instrument were collected at baseline and throughout the trial. Medical resources and medications were assigned values by using U.S. Medicare payments and wholesale acquisition costs, respectively. Secondary analyses used English costs. RESULTS: Patients were followed for an average of 3.3 years, during which time those randomized to EQW experienced 0.41 fewer inpatient days (7.05 vs. 7.46 days; relative rate ratio 0.91; P = 0.05). Rates of outpatient medical visits were similar, as were total inpatient and outpatient costs. Mean costs for nonstudy diabetes medications over the study period were ∼$1,600 lower with EQW than with placebo (P = 0.01). Total within-study costs, excluding study medication, were lower in the EQW arm than in the placebo arm ($28,907 vs. $30,914; P ≤ 0.01). When including the estimated cost of EQW, total mean costs were significantly higher in the EQW group than in the placebo group ($42,697 vs. $30,914; P < 0.01). With English costs applied, mean total costs, including exenatide costs, were £1,670 higher in the EQW group than the placebo group (£10,874 vs. £9,204; P < 0.01). There were no significant differences in EQ-5D health utilities between arms over time. CONCLUSIONS: Medical costs were lower in the EQW arm than the placebo arm, but total costs were significantly higher once the cost of branded exenatide was incorporated.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Reed SD, Li Y, Dakin HA, et al. Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care. 2019. PMID: 31806653. doi:10.2337/dc19-0950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。